Navigation
Request Briefing
Home›Company›About Us
The Company

ANIKA
STERILIS
PRIVATE LIMITED

India's premier developer and manufacturer of Advanced Active Chemical Threat Scanning systems. Protecting lives, securing infrastructure, and advancing diagnostics through active chemical intelligence — developed in-house, built in India, deployed globally.

Astor Platinum 2018 ISBS Excellence 2022 House of Commons 2022
123K
Sq.Ft manufacturing facility
100%
Indigenous IP ownership
30+
Detection domains covered
AERB
Regulatory certified
Company Profile

Advanced Detection
Built in India

Anika Sterilis develops and manufactures active chemical intelligence systems for defense, homeland security, healthcare diagnostics, aviation, border control, and industrial safety.

Our AACTS platform is engineered around active sampling, dual-axial IMS analysis, adaptive detection logic, and field-ready workflows that help operators identify trace chemical threats before they become incidents.

Corporate headquarters visual Production facility visual
Corporate Headquarters & Production Facility
Manufacturing Scale

123,842 Sq.Ft.
Integrated Facility

The AMTZ Visakhapatnam facility gives Anika Sterilis direct control over research, engineering, production, quality validation, and deployment readiness.

This vertically integrated capability supports defense-grade reliability, regulated healthcare applications, and rapid configuration for multi-domain security deployments.

Anika Sterilis integrated facility
Anika Sterilis Integrated Facility
Our Mission

Active Chemical Intelligence
for a Safer World

Anika Sterilis was founded with a singular conviction — that the most critical security and health challenges facing the world require detection systems that actively seek threats, rather than passively wait for them. AACTS® is the embodiment of that conviction.

Security Mission

To protect citizens, infrastructure, and national borders through active chemical threat detection that operates where passive systems cannot — at ng–pg sensitivity, in real-time, in any environment.

Health Mission

To democratize clinical diagnostics through non-invasive breath-based disease detection — bringing rapid, reliable disease identification to the point of care without laboratory infrastructure.

National Mission

To build India's sovereign capability in advanced chemical detection technology — developing and manufacturing world-class systems domestically, exported globally, from Indian soil.

Company Journey

Milestones

2017

Company Founded

Anika Sterilis Private Limited established with a mission to develop indigenous advanced chemical threat detection technology for Indian defense and security applications.

2017

AACTS-3000 — First System

First generation AACTS-3000 development completed. TRU-RAD dual axial IMS architecture validated. AERB licensing for Ni-63 ionization obtained.

2018

International Recognition — Astor Platinum Award

AACTS-3000 wins Best CBRNE Detection System at the prestigious Astor Platinum Awards, USA. International validation of AACTS® detection performance.

2022

AMTZ Facility — 123,842 Sq.Ft

Full-scale manufacturing facility operational at AMTZ Visakhapatnam, Andhra Pradesh. ISO 13485-aligned quality systems. End-to-end production capability from R&D through final system assembly.

2022

Healthcare Breath Analyzer — TB Validation

AACTS® breath analyzer achieves clinically validated performance for tuberculosis screening: 95.7% sensitivity, 91.3% specificity, ROC AUC 0.935 — a world-first application of IMS to non-invasive TB diagnostics.

2022

ISBS Excellence Award & House of Commons Recognition

ISBS Healthcare Technology of the Year 2022 for breath analyzer application. Recognized at the House of Commons, UK, for innovation in healthcare diagnostics technology.

2024

AACTS® Ecosystem Rebrand

AACTS-3000 established as part of the comprehensive AACTS® ecosystem naming framework. Platform expanded to cover 30+ detection domains.

2026

Global Deployment Scale

AACTS® systems deployed across defense, aviation, healthcare, and industrial domains globally. Active engagement with sovereign governments on national-scale deployment programs.

Certifications & Compliance

Certifications

AERB Certification

Atomic Energy Regulatory Board licensing for all Ni-63 ionization sources. Full regulatory compliance under AERB (Radiation Protection) Rules.

ISO 13485-Aligned

Manufacturing quality system aligned to ISO 13485 medical device quality management standards — supporting healthcare deployment certification.

Make in India

DIPP Registration No. 13936. Indigenous development and manufacturing. Eligible for government procurement under Make in India incentive frameworks.

Export Clearances

Systems cleared for international export under applicable Indian export control regulations. Deployed in multiple international jurisdictions.

Recognition

Awards & Recognition

Astor Platinum 2018

Best CBRNE Detection System — USA. International recognition of AACTS® detection performance at the world's premier CBRNE technology forum.

ISBS Excellence 2022

Healthcare Technology of the Year — International Society for Biosensors & Sensors. Recognized for breakthrough application of IMS to clinical breath diagnostics.

House of Commons 2022

Recognized at the UK House of Commons for innovation in healthcare diagnostics technology — specifically for the TB breath analyzer platform.

Strategic Partners

Key Partnerships

Clinical Research Partners

Collaborations with leading academic medical centers and research institutions for clinical validation of the AACTS® healthcare platform.

International Defense Partners

Strategic defense industry partnerships for international system integration and joint deployment programs. Contact for partner program details.

Investors · Media · Partners · Institutions

Work With Us

Whether you are a defense ministry, healthcare authority, research institution, or industry partner — contact us to explore how AACTS® can serve your mission.

Get in Touch Visit Manufacturing